Literature DB >> 26163512

The time course of resolution of adhesions during fibrinolytic therapy in tetracycline-induced pleural injury in rabbits.

Andrey A Komissarov1, Galina Florova2, Ali O Azghani3, Ann Buchanan4, William M Bradley5, Chris Schaefer2, Kathleen Koenig2, Steven Idell2.   

Abstract

The time required for the effective clearance of pleural adhesions/organization after intrapleural fibrinolytic therapy (IPFT) is unknown. Chest ultrasonography and computed tomography (CT) were used to assess the efficacy of IPFT in a rabbit model of tetracycline-induced pleural injury, treated with single-chain (sc) urokinase plasminogen activators (scuPAs) or tissue PAs (sctPA). IPFT with sctPA (0.145 mg/kg; n = 10) and scuPA (0.5 mg/kg; n = 12) was monitored by serial ultrasonography alone (n = 12) or alongside CT scanning (n = 10). IPFT efficacy was assessed with gross lung injury scores (GLIS) and ultrasonography scores (USS). Pleural fluids withdrawn at 0-240 min and 24 h after IPFT were assayed for PA and fibrinolytic activities, α-macroglobulin/fibrinolysin complexes, and active PA inhibitor 1 (PAI-1). scuPA and sctPA generated comparable steady-state fibrinolytic activities by 20 min. PA activity in the scuPA group decreased slower than the sctPA group (kobs = 0.016 and 0.042 min(-1)). Significant amounts of bioactive uPA/α-macroglobulin (but not tPA; P < 0.05) complexes accumulated at 0-40 min after IPFT. Despite the differences in intrapleural processing, IPFT with either fibrinolysin was effective (GLIS ≤ 10) in animals imaged with ultrasonography only. USS correlated well with postmortem GLIS (r(2) = 0.85) and confirmed relatively slow intrapleural fibrinolysis after IPFT, which coincided with effective clearance of adhesions/organization at 4-8 h. CT scanning was associated with less effective (GLIS > 10) IPFT and higher levels of active PAI-1 at 24 h following therapy. We concluded that intrapleural fibrinolysis in tetracycline-induced pleural injury in rabbits is relatively slow (4-8 h). In CT-scanned animals, elevated PAI-1 activity (possibly radiation induced) reduced the efficacy of IPFT, buttressing the major impact of active PAI-1 on IPFT outcomes.
Copyright © 2015 the American Physiological Society.

Entities:  

Keywords:  fibrinolysis; fibrinolytic therapy; plasminogen activator inhibitor 1; pleural injury; tissue plasminogen activator; urokinase

Mesh:

Substances:

Year:  2015        PMID: 26163512      PMCID: PMC4572422          DOI: 10.1152/ajplung.00136.2015

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  72 in total

1.  Fibrin-specificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: comparison of nine plasminogen activators in vitro.

Authors:  D V Sakharov; M Barrertt-Bergshoeff; R T Hekkenberg; D C Rijken
Journal:  Thromb Haemost       Date:  1999-04       Impact factor: 5.249

2.  Active α-macroglobulin is a reservoir for urokinase after fibrinolytic therapy in rabbits with tetracycline-induced pleural injury and in human pleural fluids.

Authors:  Andrey A Komissarov; Galina Florova; Ali Azghani; Sophia Karandashova; Anna K Kurdowska; Steven Idell
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-08-30       Impact factor: 5.464

3.  Plasminogen activator inhibitor-1 deficiency augments visceral mesothelial organization, intrapleural coagulation, and lung restriction in mice with carbon black/bleomycin-induced pleural injury.

Authors:  Torry A Tucker; Ann Jeffers; Alexia Alvarez; Shuzi Owens; Kathleen Koenig; Brandon Quaid; Andrey A Komissarov; Galina Florova; Hema Kothari; Usha Pendurthi; L Vijaya Mohan Rao; Steven Idell
Journal:  Am J Respir Cell Mol Biol       Date:  2014-02       Impact factor: 6.914

4.  Additivity in effects of vitronectin and monoclonal antibodies against alpha-helix F of plasminogen activator inhibitor-1 on its reactions with target proteinases.

Authors:  Andrey A Komissarov; Peter A Andreasen; Julie S Bødker; Paul J Declerck; John Y Anagli; Joseph D Shore
Journal:  J Biol Chem       Date:  2004-10-29       Impact factor: 5.157

5.  Treatment of complicated pleural effusion with intracavitary urokinase in children.

Authors:  F M de Benedictis; G De Giorgi; A Niccoli; S Troiani; F Rizzo; A Lemmi
Journal:  Pediatr Pulmonol       Date:  2000-06

6.  Urokinase in the management of complicated parapneumonic effusions in children.

Authors:  S Krishnan; N Amin; A J Dozor; G Stringel
Journal:  Chest       Date:  1997-12       Impact factor: 9.410

7.  In vivo changes in plasma coenzyme Q10, carotenoid, tocopherol, and retinol levels in children after computer tomography.

Authors:  Brunhild M Halm; Jennifer F Lai; Cynthia M Morrison; Ian Pagano; Laurie J Custer; Robert V Cooney; Adrian A Franke
Journal:  Arch Biochem Biophys       Date:  2014-02-25       Impact factor: 4.013

8.  Medical management of parapneumonic pleural disease.

Authors:  N P Barnes; J Hull; A H Thomson
Journal:  Pediatr Pulmonol       Date:  2005-02

9.  Further characterization of the covalent linking reaction of alpha 2-macroglobulin.

Authors:  G S Salvesen; C A Sayers; A J Barrett
Journal:  Biochem J       Date:  1981-05-01       Impact factor: 3.857

10.  The role of enzyme lysyl amino groups in the reaction with alpha 2-macroglobulin.

Authors:  R D Feinman; D Wang; S R Windwer; K Wu
Journal:  Ann N Y Acad Sci       Date:  1983       Impact factor: 5.691

View more
  6 in total

Review 1.  Fibrin turnover and pleural organization: bench to bedside.

Authors:  Andrey A Komissarov; Najib Rahman; Y C Gary Lee; Galina Florova; Sreerama Shetty; Richard Idell; Mitsuo Ikebe; Kumuda Das; Torry A Tucker; Steven Idell
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-01-18       Impact factor: 5.464

Review 2.  Intrapleural Fibrinolytic Therapy for Empyema and Pleural Loculation: Knowns and Unknowns.

Authors:  Steven Idell; Najib M Rahman
Journal:  Ann Am Thorac Soc       Date:  2018-05

3.  Phase 1 trial of intrapleural LTI-01; single chain urokinase in complicated parapneumonic effusions or empyema.

Authors:  Lutz Beckert; Ben Brockway; Graham Simpson; Anne Marie Southcott; Y C Gary Lee; Najib Rahman; Richard W Light; Steven Shoemaker; John Gillies; Andrey A Komissarov; Galina Florova; Timothy Ochran; William Bradley; Harrison Ndetan; Karan P Singh; Krishna Sarva; Steven Idell
Journal:  JCI Insight       Date:  2019-04-18

4.  Targeting plasminogen activator inhibitor-1 in tetracycline-induced pleural injury in rabbits.

Authors:  Galina Florova; Ali O Azghani; Sophia Karandashova; Chris Schaefer; Serge V Yarovoi; Paul J Declerck; Douglas B Cines; Steven Idell; Andrey A Komissarov
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-08-31       Impact factor: 5.464

5.  Precision targeting of the plasminogen activator inhibitor-1 mechanism increases efficacy of fibrinolytic therapy in empyema.

Authors:  Galina Florova; René A Girard; Ali O Azghani; Krishna Sarva; Ann Buchanan; Sophia Karandashova; Christian J DeVera; Danna Morris; Mignote Chamiso; Kathleen Koenig; Douglas B Cines; Steven Idell; Andrey A Komissarov
Journal:  Physiol Rep       Date:  2021-05

6.  Dose dependency of outcomes of intrapleural fibrinolytic therapy in new rabbit empyema models.

Authors:  Andrey A Komissarov; Galina Florova; Ali O Azghani; Ann Buchanan; Jake Boren; Timothy Allen; Najib M Rahman; Kathleen Koenig; Mignote Chamiso; Sophia Karandashova; James Henry; Steven Idell
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-06-24       Impact factor: 5.464

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.